PE shops Nordic Capital and Avista sold 375 million shares at £2.60 apiece in the over-subscribed offering, after raising the float from 300 million shares, according to bookrunner UBS.
Other investors sold another 389 million shares, or about 20% of ConvaTec, to Novo Nordisk (NYSE:NVO) for about $1.25 billion (£1.01 billion). Novo CEO Kasim Kutay is slated to join the Reading, U.K.-based company’s board, the Danish diabetes giant said.
“ConvaTec is a very attractive investment opportunity given the fundamentals of the medical products sector and the strength of the company’s product portfolio. I look forward to joining the board of directors of ConvaTec and working with Sir Christopher Gent and the other directors,” Kutay said in prepared remarks.
CTEC shares were up 1.6% to £2.73 apiece in London today. Nordic still owns a 16.1% stake (314 million shares), with Avista retaining a 7.0% stake (137 million shares). None of the proceeds will go to ConvaTec.
The wound care and colostomy supply maker last October grossed nearly $1.8 billion on the London Stock Exchange in an initial public offering. Earlier this month, ConvaTec reported an 8% increase in annual operating profit for 2016, as margin growth topped expectations.
($1 = £0.807)
Material from Reuters was used in this report.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.